MADRIGAL PHARMACEUTICALS, INC. Net Cash Provided by (Used in) Continuing Operations
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Net Cash Provided by (Used in) Continuing Operations of -$10.93 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-11.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:NetCashProvidedByUsedInContinuingOperations · last filed 2017-05-11
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) continuing operations for the quarter ending 2017-03-31 was -$10.93M, a 3603.21% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) continuing operations for the quarter ending 2016-12-31 was $10.75M, a 4138.08% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) continuing operations for the quarter ending 2016-09-30 was $32.30M, a 131.93% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) continuing operations for the quarter ending 2016-06-30 was -$24.52M.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) continuing operations for fiscal 2016 was $18.84M, a 11809.46% increase from fiscal 2015.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) continuing operations for fiscal 2015 was $158.18K.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) continuing operations for fiscal 2014 was -$2.47M.
- MADRIGAL PHARMACEUTICALS, INC. net cash provided by (used in) continuing operations for fiscal 2013 was -$33.02M, a 164.20% decline from fiscal 2012.
| Period end | Net Cash Provided by (Used in) Continuing Operations 3 month | Net Cash Provided by (Used in) Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Continuing Operations 6 month | Net Cash Provided by (Used in) Continuing Operations 9 month | Net Cash Provided by (Used in) Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Continuing Operations 12 month | Net Cash Provided by (Used in) Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2017-03-31 | -$10.93M 10-Q · filed 2017-05-11 | -$178.32K derived: sum of 2 quarters · filed 2017-05-11 | $32.12M derived: sum of 3 quarters · filed 2017-05-11 | $7.60M derived: sum of 4 quarters · filed 2017-05-11 | |||
| 2016-12-31 | $10.75M derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-31 | $43.05M derived: sum of 2 quarters · filed 2017-03-31 | $18.53M derived: sum of 3 quarters · filed 2017-03-31 | $18.84M 10-K · filed 2017-03-31 | |||
| 2016-09-30 | $32.30M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2017-03-31 | $7.78M derived: sum of 2 quarters · filed 2017-03-31 | $8.09M 10-Q/A · filed 2017-03-31 | $8.34M derived: sum of 4 quarters · filed 2017-05-11 | |||
| 2016-06-30 | -$24.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-20 | -$24.21M 10-Q · filed 2016-07-20 | -$23.96M derived: sum of 3 quarters · filed 2017-05-11 | -$10.03M derived: sum of 4 quarters · filed 2017-05-11 | |||
| 2016-03-31 | $312.00K 10-Q · filed 2017-05-11 | $7.85M 10-Q · filed 2016-05-10 | $565.69K derived: sum of 2 quarters · filed 2017-05-11 | $14.49M derived: sum of 3 quarters · filed 2017-05-11 | $13.24M derived: sum of 4 quarters · filed 2017-05-11 | ||
| 2015-12-31 | $253.69K derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-31 | $14.18M derived: sum of 2 quarters · filed 2017-03-31 | $12.93M derived: sum of 3 quarters · filed 2017-03-31 | $158.18K 10-K · filed 2017-03-31 | -$11.06M 10-K · filed 2016-03-15 | ||
| 2015-09-30 | $13.93M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2017-03-31 | $12.67M derived: sum of 2 quarters · filed 2017-03-31 | -$95.51K 10-Q/A · filed 2017-03-31 | -$487.00K 10-Q · filed 2015-11-05 | -$22.55M derived: sum of 4 quarters · filed 2017-03-31 | ||
| 2015-06-30 | -$1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-20 | -$14.02M 10-Q · filed 2016-07-20 | -$36.48M derived: sum of 3 quarters · filed 2016-07-20 | -$64.81M derived: sum of 4 quarters · filed 2016-07-20 | |||
| 2015-03-31 | -$12.77M 10-Q · filed 2016-05-10 | -$35.22M derived: sum of 2 quarters · filed 2016-05-10 | -$63.56M derived: sum of 3 quarters · filed 2016-05-10 | -$18.78M derived: sum of 4 quarters · filed 2016-05-10 | |||
| 2014-12-31 | -$22.45M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$50.79M derived: sum of 2 quarters · filed 2016-03-15 | -$6.01M derived: sum of 3 quarters · filed 2016-03-15 | -$2.47M 10-K · filed 2016-03-15 | |||
| 2014-09-30 | -$28.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $16.44M derived: sum of 2 quarters · filed 2015-11-05 | $19.99M 10-Q · filed 2015-11-05 | $43.00M derived: sum of 4 quarters · filed 2016-03-15 | |||
| 2014-06-30 | $44.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $48.32M 10-Q · filed 2015-08-06 | $71.33M derived: sum of 3 quarters · filed 2016-03-15 | $63.03M derived: sum of 4 quarters · filed 2016-03-15 | |||
| 2014-03-31 | $3.54M 10-Q · filed 2015-05-07 | $26.56M derived: sum of 2 quarters · filed 2016-03-15 | $18.25M derived: sum of 3 quarters · filed 2016-03-15 | $17.07M derived: sum of 4 quarters · filed 2016-03-15 | |||
| 2013-12-31 | $23.01M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $14.71M derived: sum of 2 quarters · filed 2016-03-15 | $13.53M derived: sum of 3 quarters · filed 2016-03-15 | -$33.02M 10-K · filed 2016-03-15 | |||
| 2013-09-30 | -$8.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$9.48M derived: sum of 2 quarters · filed 2014-11-06 | -$56.03M 10-Q · filed 2014-11-06 | -$3.96M derived: sum of 4 quarters · filed 2015-03-12 | |||
| 2013-06-30 | -$1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | -$47.73M 10-Q · filed 2014-08-06 | $4.34M derived: sum of 3 quarters · filed 2015-03-12 | $8.19M derived: sum of 4 quarters · filed 2015-03-12 | |||
| 2013-03-31 | -$46.55M 10-Q · filed 2014-05-08 | $5.52M derived: sum of 2 quarters · filed 2015-03-12 | $9.37M derived: sum of 3 quarters · filed 2015-03-12 | $412.00K derived: sum of 4 quarters · filed 2015-03-12 | |||
| 2012-12-31 | $52.07M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $55.92M derived: sum of 2 quarters · filed 2015-03-12 | $46.96M derived: sum of 3 quarters · filed 2015-03-12 | $51.44M 10-K · filed 2015-03-12 | |||
| 2012-09-30 | $3.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-04 | -$5.11M derived: sum of 2 quarters · filed 2013-11-04 | -$633.00K 10-Q · filed 2013-11-04 | $8.80M derived: sum of 4 quarters · filed 2014-03-11 | |||
| 2012-06-30 | -$8.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | -$4.48M 10-Q · filed 2013-08-01 | $4.95M derived: sum of 3 quarters · filed 2014-03-11 | -$298.00K derived: sum of 4 quarters · filed 2014-03-11 | |||
| 2012-03-31 | $4.47M 10-Q · filed 2013-04-30 | $13.91M derived: sum of 2 quarters · filed 2014-03-11 | $8.66M derived: sum of 3 quarters · filed 2014-03-11 | $17.18M derived: sum of 4 quarters · filed 2014-03-11 | |||
| 2011-12-31 | $9.43M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-11 | $4.18M derived: sum of 2 quarters · filed 2014-03-11 | $12.70M derived: sum of 3 quarters · filed 2014-03-11 | -$1.24M 10-K · filed 2014-03-11 | |||
| 2011-09-30 | -$5.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $3.27M derived: sum of 2 quarters · filed 2012-11-06 | -$10.67M 10-Q · filed 2012-11-06 | -$14.26M derived: sum of 4 quarters · filed 2013-03-14 | |||
| 2011-06-30 | $8.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | -$5.42M 10-Q · filed 2012-08-02 | -$9.02M derived: sum of 3 quarters · filed 2013-03-14 | ||||
| 2011-03-31 | -$13.94M 10-Q · filed 2012-05-03 | -$17.53M derived: sum of 2 quarters · filed 2013-03-14 | |||||
| 2010-12-31 | -$3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-14 | -$12.85M 10-K · filed 2013-03-14 | |||||
| 2010-09-30 | -$9.25M 10-Q · filed 2011-11-03 | ||||||
| 2009-12-31 | -$7.89M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |